Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
17.95
-0.66 (-3.55%)
At close: Mar 5, 2026, 4:00 PM EST
17.90
-0.05 (-0.28%)
After-hours: Mar 5, 2026, 6:36 PM EST
Monte Rosa Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Monte Rosa Therapeutics stock have an average target of 29.5, with a low estimate of 17 and a high estimate of 37. The average target predicts an increase of 64.35% from the current stock price of 17.95.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 14, 2026.
Analyst Ratings
The average analyst rating for Monte Rosa Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Buy | 2 | 2 | 1 | 2 | 3 | 3 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 2 | 2 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $28 → $37 | Buy | Reiterates | $28 → $37 | +106.13% | Jan 14, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $22 → $30 | Buy | Maintains | $22 → $30 | +67.13% | Jan 8, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $16 → $34 | Strong Buy | Maintains | $16 → $34 | +89.42% | Jan 8, 2026 |
| Wells Fargo | Wells Fargo | Hold → Buy Upgrades $13 → $22 | Hold → Buy | Upgrades | $13 → $22 | +22.56% | Dec 16, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $10 → $13 | Hold | Maintains | $10 → $13 | -27.58% | Nov 7, 2025 |
Financial Forecast
Revenue This Year
139.16M
from 75.62M
Increased by 84.02%
Revenue Next Year
56.84M
from 139.16M
Decreased by -59.16%
EPS This Year
-0.28
from -0.98
EPS Next Year
-1.30
from -0.28
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 169.0M | 200.6M | ||||
| Avg | 139.2M | 56.8M | ||||
| Low | 118.6M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 123.4% | 44.1% | ||||
| Avg | 84.0% | -59.2% | ||||
| Low | 56.8% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.04 | 0.26 | ||||
| Avg | -0.28 | -1.30 | ||||
| Low | -0.44 | -1.93 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.